Compare · ITGR vs LIVN
ITGR vs LIVN
Side-by-side comparison of Integer Holdings Corporation (ITGR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITGR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.32B, about the same size as ITGR ($4.31B).
- ITGR has been more active in the news (6 items in the past 4 weeks vs 2 for LIVN).
- ITGR has more recent analyst coverage (23 ratings vs 21 for LIVN).
- Company
- Integer Holdings Corporation
- LivaNova PLC
- Price
- -
- -
- Market cap
- $4.31B
- $4.32B
- 1M return
- -
- -0.29%
- 1Y return
- -
- +44.35%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 2
- Recent ratings
- 23
- 21
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest ITGR
- SEC Form 3 filed by Integer Holdings Corporation
- SEC Form 8-K filed by Integer Holdings Corporation
- Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028
- Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Integer Receives Early Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition by KKR
- Chief Human Resources Officer Thor Kirk K sold $3,981,726 worth of shares (31,540 units at $126.24), decreasing direct ownership by 82% to 7,153 units (SEC Form 4)
- SEC Form DEFM14A filed by Integer Holdings Corporation
- President, Growth & Innovation Senn Andrew sold $1,188,230 worth of shares (9,408 units at $126.30), decreasing direct ownership by 64% to 5,405 units (SEC Form 4)
- SEC Form PREM14A filed by Integer Holdings Corporation
Latest LIVN
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
- Director Bianchi Francesco sold $273,032 worth of Ordinary Shares (3,500 units at $78.01), decreasing direct ownership by 44% to 4,434 units (SEC Form 4)
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC